Alethio clinches $90M to advance antibody for essential thrombocythemia
About a year after emerging from stealth, University of Oxford spinout Alethio Therapeutics has collected $90 million in a Series A raise to support its lead rare blood cancer program through ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.